Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress

Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and partner Eisai will present data on real-world use of lecanemab at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), to be held in Vienna, Austria, and virtually April 1-5. In total, lecanemab will be featured in six presentations and exidavnemab in one presentation.

The release as fetched from its publisher. bioarctic.com ↗